Chemotherapy-associated liver injury: Impact on surgical management of colorectal cancer liver metastases

Annals of Surgical Oncology

Volumn 18, Issue 1, 2011, Pages 181-190

  Kneuertz, Peter J ^a   Maithel, Shishir K ^a   Staley, Charles A ^a   Kooby, David A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADD ON THERAPY; ARTICLE; ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER SURGERY; CHEMOTHERAPY ASSOCIATED FATTY LIVER; COLORECTAL CANCER; DIABETES MELLITUS; DISEASE CLASSIFICATION; FATTY LIVER; HEPATIC PEDICLE CLAMPING; HUMAN; HYPERLIPIDEMIA; LIVER FAILURE; LIVER METASTASIS; LIVER RESECTION; LIVER SURGERY; LUNG DISEASE; MULTIPLE CYCLE TREATMENT; NONALCOHOLIC FATTY LIVER; OBESITY; OPERATION DURATION; OUTCOME ASSESSMENT; PORTAL VEIN; PREOPERATIVE PERIOD; SEPSIS; SINUSOIDAL DILATATION; SINUSOIDAL OBSTRUCTION SYNDROME; TIME; TOXIC HEPATITIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG-INDUCED LIVER INJURY; HUMANS; LIVER NEOPLASMS; PROGNOSIS;

EID: 78651363729     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-1201-2     Document Type: Article

References (78)

1. P Thirion S Michiels JP Pignon, et al. 2004 Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis J Clin Oncol. 22 3766 3775 1:STN:280:DC%2BD2cvls1Cquw%3D%3D 10.1200/JCO.2004.03.104 15365073
2. MA Choti JV Sitzmann MF Tiburi, et al. 2002 Trends in long-term survival following liver resection for hepatic colorectal metastases Ann Surg. 235 759 766 10.1097/00000658-200206000-00002 12035031
3. Y Fong J Fortner RL Sun MF Brennan LH Blumgart 1999 Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases Ann Surg. 230 309 318 1:STN:280: DyaK1MvitFahsw%3D%3D 10.1097/00000658-199909000-00004 10493478 discussion 318-21
4. MA Adson JA van Heerden MH Adson JS Wagner DM Ilstrup 1984 Resection of hepatic metastases from colorectal cancer Arch Surg. 119 647 651 1:STN:280:DyaL2c3jtVKntw%3D%3D 6732473
5. C Tournigand T Andre E Achille, et al. 2004 FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol. 22 229 237 1:CAS:528:DC%2BD2cXpsVKit7w%3D 10.1200/JCO.2004.05.113 14657227
6. A de Gramont A Figer M Seymour, et al. 2000 Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol. 18 2938 2947 10944126
7. FG Fernandez JA Drebin DC Linehan F Dehdashti BA Siegel SM Strasberg 2004 Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with f-18 fluorodeoxyglucose (FDG-PET) Ann Surg. 240 438 447 10.1097/01.sla.0000138076. 72547.b1 15319715 discussion 447-50
8. EK Abdalla JN Vauthey LM Ellis, et al. 2004 Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases Ann Surg. 239 818 825 10.1097/01.sla.0000128305.90650.71 15166961 discussion 825-7
9. B Nordlinger H Sorbye B Glimelius, et al. 2008 Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC intergroup trial 40983): a randomised controlled trial Lancet. 371 1007 1016 1:CAS:528:DC%2BD1cXjs1Sltbg%3D 10.1016/S0140- 6736(08)60455-9 18358928
10. DA Kooby Y Fong A Suriawinata, et al. 2003 Impact of steatosis on perioperative outcome following hepatic resection J Gastrointest Surg. 7 1034 1044 10.1016/j.gassur.2003.09.012 14675713
11. JN Vauthey TM Pawlik D Ribero, et al. 2006 Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases J Clin Oncol. 24 2065 2072 1:CAS:528:DC%2BD28Xlt1amurY%3D 10.1200/JCO.2005.05.3074 16648507
12. L Rubbia-Brandt G Mentha B Terris 2006 Sinusoidal obstruction syndrome is a major feature of hepatic lesions associated with oxaliplatin neoadjuvant chemotherapy for liver colorectal metastases J Am Coll Surg. 202 199 200 10.1016/j.jamcollsurg.2005.09.010 16377516
13. M Hilden P Christoffersen E Juhl JB Dalgaard 1977 Liver histology in a 'normal' population-examinations of 503 consecutive fatal traffic casualties Scand J Gastroenterol. 12 593 597 1:STN:280:DyaE1c%2FjsVSjsA%3D%3D 10.3109/00365527709181339 918553
14. P Hornboll TS Olsen 1982 Fatty changes in the liver: the relation to age, overweight and diabetes mellitus Acta Pathol Microbiol Immunol Scand A. 90 199 205 1:STN:280:DyaL383ltlajtg%3D%3D 7102315
15. SG Hubscher 2006 Histological assessment of non-alcoholic fatty liver disease Histopathology. 49 450 465 1:STN:280:DC%2BD28njtFaiug%3D%3D 10.1111/j.1365-2559.2006.02416.x 17064291
16. AM D'Alessandro M Kalayoglu HW Sollinger, et al. 1991 The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation Transplantation. 51 157 163 10.1097/00007890-199101000-00024 1987685
17. MR Teli OF James AD Burt MK Bennett CP Day 1995 The natural history of nonalcoholic fatty liver: a follow-up study Hepatology. 22 1714 1719 1:STN:280:DyaK28%2FovVyhtQ%3D%3D 10.1002/hep.1840220616 7489979
18. Y Fong DJ Bentrem 2006 CASH (chemotherapy-associated steatohepatitis) costs Ann Surg. 243 8 9 10.1097/01.sla.0000193599.57858.9b 16371729
19. CP Day OF James 1998 Hepatic steatosis: innocent bystander or guilty party? Hepatology. 27 1463 1466 1:STN:280:DyaK1c3otFKhtg%3D%3D 10.1002/hep.510270601 9620314
20. SC Lim JE Choi HS Kang S Iy Han 2010 Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma Int J Cancer. 126 1582 1595 1:CAS:528:DC%2BC3cXhtl2it7w%3D 19728331
21. Z Li H Lin S Yang AM Diehl 2002 Murine leptin deficiency alters Kupffer cell production of cytokines that regulate the innate immune system Gastroenterology. 123 1304 1310 1:CAS:528:DC%2BD38Xotl2nsLY%3D 10.1053/gast.2002.35997 12360490
22. AM Diehl 2002 Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines Am J Physiol Gastrointest Liver Physiol. 282 G1 G5 1:CAS:528:DC%2BD38XlsVKrug%3D%3D 11751151
23. R Vetelainen AK van Vliet TM van Gulik 2007 Severe steatosis increases hepatocellular injury and impairs liver regeneration in a rat model of partial hepatectomy Ann Surg. 245 44 50 10.1097/01.sla.0000225253.84501.0e 17197964
24. DE Kleiner EM Brunt M Van Natta, et al. 2005 Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology. 41 1313 1321 10.1002/hep.20701 15915461
25. LD DeLeve HM Shulman GB McDonald 2002 Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease) Semin Liver Dis. 22 27 42 10.1055/s-2002-23204 11928077
26. T Aloia M Sebagh M Plasse, et al. 2006 Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases J Clin Oncol. 24 4983 4990 1:CAS:528:DC%2BD28Xht1GnurzI 10.1200/JCO.2006.05.8156 17075116
27. L Rubbia-Brandt V Audard P Sartoretti, et al. 2004 Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer Ann Oncol. 15 460 466 1:STN:280:DC%2BD2c7gvVeksQ%3D%3D 10.1093/annonc/mdh095 14998849
28. A Brouquet S Benoist C Julie C Penna A Beauchet P Rougier, et al. 2009 Risk factors for chemotherapy-associated liver injuries: a multivariate analysis of a group of 146 patients with colorectal metastases Surgery. 145 362 371 10.1016/j.surg.2008.12.002 19303984
29. J Zeiss HW Merrick ER Savolaine LS Woldenberg K Kim PJ Schlembach 1990 Fatty Liver Change as a Result of Hepatic Artery Infusion Chemotherapy Am J Clin Oncol. 13 156 160 1:STN:280:DyaK3c7psF2nsg%3D%3D 10.1097/00000421-199004000- 00013 2138409
30. CG Moertel TR Fleming JS Macdonald DG Haller JA Laurie 1993 Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy J Clin Oncol. 11 2386 2390 1:STN:280:DyaK2c%2FmsFyksg%3D%3D 8246027
31. PD Peppercorn RH Reznek P Wilson ML Slevin RK Gupta 1998 Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer Br J Cancer. 77 2008 2011 1:STN:280:DyaK1czjtVamtQ%3D%3D 9667683
32. P Sorensen AL Edal EL Madsen C Fenger MR Poulsen OF Petersen 1995 Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil Cancer. 75 2592 2596 1:STN:280:DyaK2M3lsVCmsw%3D%3D 10.1002/1097-0142(19950515)75:10<2592::AID-CNCR2820751029>3.0.CO;2-G 7736406
33. FG Fernandez J Ritter JW Goodwin DC Linehan WG Hawkins SM Strasberg 2005 Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases J Am Coll Surg. 200 845 853 10.1016/j.jamcollsurg.2005.01.024 15922194
34. M Karoui C Penna M Amin-Hashem, et al. 2006 Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases Ann Surg. 243 1 7 10.1097/01.sla.0000193603.26265.c3 16371728
35. D Ribero H Wang M Donadon, et al. 2007 Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases Cancer. 110 2761 2767 10.1002/cncr.23099 17960603
36. M Klinger S Eipeldauer S Hacker, et al. 2009 Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases Eur J Surg Oncol. 35 515 520 1:STN:280:DC%2BD1M3ltlyrtg%3D%3D 19200687
37. KE Behrns GG Tsiotos NF DeSouza MK Krishna J Ludwig DM Nagorney 1998 Hepatic steatosis as a potential risk factor for major hepatic resection J Gastrointest Surg. 2 292 298 1:STN:280:DyaK1M%2FlvF2ksQ%3D%3D 10.1016/S1091-255X(98)80025-5 9841987
38. J Belghiti K Hiramatsu S Benoist P Massault A Sauvanet O Farges 2000 Seven hundred forty-seven hepatectomies in the 1990 s: an update to evaluate the actual risk of liver resection J Am Coll Surg. 191 38 46 1:STN:280: DC%2BD3czlsVGntQ%3D%3D 10.1016/S1072-7515(00)00261-1 10898182
39. L McCormack H Petrowsky W Jochum K Furrer PA Clavien 2007 Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study Ann Surg. 245 923 930 10.1097/01.sla.0000251747.80025.b7 17522518
40. D Gomez HZ Malik GK Bonney V Wong GJ Toogood JP Lodge, et al. 2007 Steatosis predicts postoperative morbidity following hepatic resection for colorectal metastasis Br J Surg. 94 1395 1402 1:STN:280:DC%2BD2snjtVGqtg%3D%3D 10.1002/bjs.5820 17607707
41. DA Kooby J Stockman L Ben-Porat, et al. 2003 Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases Ann Surg. 237 860 869 10.1097/00000658-200306000-00015 12796583 discussion 869-70
42. H Nakano E Oussoultzoglou E Rosso, et al. 2008 Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy Ann Surg. 247 118 124 10.1097/SLA.0b013e31815774de 18156931
43. S Kandutsch M Klinger S Hacker F Wrba B Gruenberger T Gruenberger 2008 Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases Eur J Surg Oncol. 34 1231 1236 1:STN:280:DC%2BD1cnos1yjtQ%3D%3D 18272318
44. C Hubert C Fervaille C Sempoux, et al. 2010 Prevalence and clinical relevance of pathological hepatic changes occurring after neoadjuvant chemotherapy for colorectal liver metastases Surgery. 147 185 194 10.1016/j.surg.2009.01.004 20109620
45. DA Kooby KL Zakian SN Challa, et al. 2000 Use of phosphorous-31 nuclear magnetic resonance spectroscopy to determine safe timing of chemotherapy after hepatic resection Cancer Res. 60 3800 3806 1:CAS:528:DC%2BD3cXlt1Gkt7o%3D 10919653
46. FK Welsh HS Tilney PP Tekkis TG John M Rees 2007 Safe liver resection following chemotherapy for colorectal metastases is a matter of timing Br J Cancer. 96 1037 1042 1:STN:280:DC%2BD2s3gt12jtA%3D%3D 10.1038/sj.bjc.6603670 17353923
47. OM Jones M Rees TG John S Bygrave G Plant 2005 Biopsy of resectable colorectal liver metastases causes tumour dissemination and adversely affects survival after liver resection Br J Surg. 92 1165 1168 1:STN:280: DC%2BD2MvkvVKltQ%3D%3D 10.1002/bjs.4888 15997444
48. V Ratziu F Charlotte A Heurtier, et al. 2005 Sampling variability of liver biopsy in nonalcoholic fatty liver disease Gastroenterology. 128 1898 1906 10.1053/j.gastro.2005.03.084 15940625
49. AM El-Badry S Breitenstein W Jochum, et al. 2009 Assessment of hepatic steatosis by expert pathologists: the end of a gold standard Ann Surg. 250 691 697 10.1097/SLA.0b013e3181bcd6dd 19806055
50. D Zorzi A Laurent TM Pawlik GY Lauwers JN Vauthey EK Abdalla 2007 Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases Br J Surg. 94 274 286 1:CAS:528:DC%2BD2sXkt12nt7s%3D 10.1002/bjs.5719 17315288
51. NF Schwenzer F Springer C Schraml N Stefan J Machann F Schick 2009 Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance J Hepatol. 51 433 445 10.1016/j.jhep.2009.05.023 19604596
52. LS Szczepaniak P Nurenberg D Leonard, et al. 2005 Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population Am J Physiol Endocrinol Metab. 288 E462 E468 1:CAS:528:DC%2BD2MXhsVCktLg%3D 10.1152/ajpendo.00064.2004 15339742
53. P Sharma DR Martin N Pineda Q Xu M Vos F Anania, et al. 2009 Quantitative analysis of T2-correction in single-voxel magnetic resonance spectroscopy of hepatic lipid fraction J Magn Reson Imaging. 29 629 635 10.1002/jmri.21682 19243059
54. CS Cho S Curran LH Schwartz, et al. 2008 Preoperative radiographic assessment of hepatic steatosis with histologic correlation J Am Coll Surg. 206 480 488 10.1016/j.jamcollsurg.2007.08.020 18308219
55. S Saadeh ZM Younossi EM Remer, et al. 2002 The utility of radiological imaging in nonalcoholic fatty liver disease Gastroenterology. 123 745 750 10.1053/gast.2002.35354 12198701
56. MR Oliva KJ Mortele E Segatto JN Glickman SM Erturk PR Ros, et al. 2006 Computed tomography features of nonalcoholic steatohepatitis with histopathologic correlation J Comput Assist Tomogr. 30 37 43 10.1097/01.rct.0000193818.31749.84 16365570
57. TR O'Rourke FK Welsh PP Tekkis, et al. 2009 Accuracy of liver-specific magnetic resonance imaging as a predictor of chemotherapy-associated hepatic cellular injury prior to liver resection Eur J Surg Oncol. 35 1085 1091 19246171
58. J Ward JA Guthrie MB Sheridan, et al. 2008 Sinusoidal obstructive syndrome diagnosed with superparamagnetic iron oxide-enhanced magnetic resonance imaging in patients with chemotherapy-treated colorectal liver metastases J Clin Oncol. 26 4304 4310 10.1200/JCO.2008.16.1893 18779617
59. EK Abdalla R Adam AJ Bilchik D Jaeck JN Vauthey D Mahvi 2006 Improving Resectability of Hepatic Colorectal Metastases: Expert Consensus Statement Ann Surg Oncol. 13 1271 1280 10.1245/s10434-006-9045-5 16955381
60. OJ Garden M Rees GJ Poston, et al. 2006 Guidelines for resection of colorectal cancer liver metastases Gut 55 Suppl 3 iii1 iii8 10.1136/gut.2006. 098053 16835351
61. A Ferrero L Vigano R Polastri A Muratore H Eminefendic D Regge, et al. 2007 Postoperative liver dysfunction and future remnant liver: where is the limit? Results of a prospective study World J Surg. 31 1643 1651 10.1007/s00268-007-9123-2 17551779
62. DC Madoff ME Hicks EK Abdalla JS Morris JN Vauthey 2003 Portal vein embolization with polyvinyl alcohol particles and coils in preparation for major liver resection for hepatobiliary malignancy: safety and effectiveness study in 26 patients Radiology 227 251 260 10.1148/radiol.2271012010 12616006
63. JN Vauthey A Chaoui KA Do, et al. 2000 Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations Surgery. 127 512 519 1:STN:280:DC%2BD3c3nvFSgsw%3D%3D 10.1067/msy.2000.105294 10819059
64. M Shoup M Gonen M D'Angelica, et al. 2003 Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection J Gastrointest Surg. 7 325 330 10.1016/S1091-255X(02)00370-0 12654556
65. O Farges J Belghiti R Kianmanesh, et al. 2003 Portal vein embolization before right hepatectomy: prospective clinical trial Ann Surg. 237 208 217 10.1097/00000658-200302000-00010 12560779
66. D Azoulay D Castaing A Smail, et al. 2000 Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization Ann Surg. 231 480 486 1:STN:280:DC%2BD3c3htlaisw%3D%3D 10.1097/00000658-200004000-00005 10749607
67. CK Sun XY Zhang A Zimmermann G Davis AM Wheatley 2001 Effect of ischemia-reperfusion injury on the microcirculation of the steatotic liver of the Zucker rat Transplantation. 72 1625 1631 1:STN:280:DC%2BD3MnosVehtw%3D%3D 10.1097/00007890-200111270-00008 11726821
68. M Selzner PA Clavien 2000 Failure of regeneration of the steatotic rat liver: disruption at two different levels in the regeneration pathway Hepatology. 31 35 42 1:STN:280:DC%2BD3c%2FotVynug%3D%3D 10.1002/hep.510310108 10613725
69. C Huguet A Gavelli S Bona 1994 Hepatic resection with ischemia of the liver exceeding one hour J Am Coll Surg. 178 454 458 1:STN:280: DyaK2c3itFegsA%3D%3D 8167881
70. J Belghiti R Noun R Malafosse, et al. 1999 Continuous versus intermittent portal triad clamping for liver resection: a controlled study Ann Surg. 229 369 375 1:STN:280:DyaK1M7nsVKltQ%3D%3D 10.1097/00000658-199903000-00010 10077049
71. JC Hewes S Dighe RW Morris RR Hutchins S Bhattacharya BR Davidson 2007 Preoperative chemotherapy and the outcome of liver resection for colorectal metastases World J Surg. 31 353 364 1:STN:280:DC%2BD2s3hsVCmsw%3D%3D 10.1007/s00268-006-0103-8 17219289 discussion 365-6
72. A Sahajpal CM Vollmer Jr E Dixon, et al. 2007 Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes J Surg Oncol. 95 22 27 1:CAS:528:DC%2BD2sXhs12hs78%3D 10.1002/jso.20632 17066435
73. MM Aloysius AM Zaitoun IJ Beckingham KR Neal GP Aithal EM Bessell, et al. 2007 The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study Virchows Arch. 451 943 948 1:CAS:528:DC%2BD2sXht1KkurrL 10.1007/s00428-007-0497-1 17805566
74. TM Pawlik K Olino AL Gleisner M Torbenson R Schulick MA Choti 2007 Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome J Gastrointest Surg. 11 860 868 10.1007/s11605-007-0149-4 17492335
75. NN Mehta R Ravikumar CA Coldham, et al. 2008 Effect of preoperative chemotherapy on liver resection for colorectal liver metastases Eur J Surg Oncol. 34 782 786 1:STN:280:DC%2BD1czovVGltQ%3D%3D 18160247
76. CR Scoggins ML Campbell CS Landry BA Slomiany CE Woodall KM McMasters, et al. 2009 Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases Ann Surg Oncol. 16 35 41 10.1245/s10434-008-0190-x 18987915
77. AA Parikh B Gentner TT Wu SA Curley LM Ellis JN Vauthey 2003 Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy J Gastrointest Surg. 7 1082 1088 10.1016/j.gassur.2003.08.005 14675719
78. K Tanaka R Adam H Shimada D Azoulay F Levi H Bismuth 2003 Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver Br J Surg. 90 963 969 1:STN:280:DC%2BD3szntVSltA%3D%3D 10.1002/bjs.4160 12905549